AR and neoplasm: More recently, CRIF1 was seen to be highly expressed, together with STAT3, in the epithelium and stroma of prostate cancer and to compete with the coactivator p160 for the binding to the androgen receptor (AR), which is known to have a pro-tumorigenic role in this neoplasia [55].